The ICD-10 code for acute myeloid leukemia (AML) is C92.0, classified under “Acute myeloblastic leukemia, not having achieved remission.” But if you’re searching for “acute myeloid leukemia ICD-10 classification and beyond,” you probably need more than a single code. AML has multiple ICD-10 subcodes depending on remission status, subtype, and clinical context — and the WHO classification system adds another critical layer that shapes prognosis and treatment decisions.
Here’s the reality: coding AML correctly matters more than most people realize. Inaccurate coding affects reimbursement, clinical trial eligibility, cancer registry data, and even survival statistics. This guide covers every ICD-10 code relevant to AML, how they map to the WHO 2022 classification, the genetic mutations that actually drive prognosis, and what clinicians and coders need to get right.
Complete ICD-10 Codes for AML
AML doesn’t live under a single code. The ICD-10-CM system breaks it into several categories based on subtype and remission status. Here’s the full picture:
| ICD-10 Code | Description | Key Notes |
|---|---|---|
| C92.0 | Acute myeloblastic leukemia, not having achieved remission | Most commonly used at initial diagnosis |
| C92.01 | Acute myeloblastic leukemia, in remission | Used after successful induction therapy |
| C92.02 | Acute myeloblastic leukemia, in relapse | Disease recurrence after prior remission |
| C92.4 | Acute promyelocytic leukemia (APL) | Distinct biology — t(15;17)/PML-RARA |
| C92.5 | Acute myelomonocytic leukemia | FAB subtype M4 |
| C92.6 | Acute myeloid leukemia with 11q23 abnormality | KMT2A (MLL) rearrangements |
| C93.0 | Acute monoblastic/monocytic leukemia | FAB subtypes M5a and M5b |
| C94.0 | Acute erythroid leukemia | FAB subtype M6 |
| C94.2 | Acute megakaryoblastic leukemia | FAB subtype M7 |
A common mistake: using C92.0 as a catch-all for every AML case. If you’re coding acute promyelocytic leukemia (APL), that’s C92.4 — and getting this wrong has downstream consequences for registry data and treatment protocol tracking.
Beyond ICD-10: The WHO 2022 Classification
ICD-10 codes tell you what to bill. The WHO classification tells you what you’re actually treating. The 2022 WHO 5th edition overhauled how we categorize AML, shifting heavily toward genetics-first classification.
Under the current WHO system, AML is diagnosed when blast count reaches ≥20% in bone marrow or peripheral blood — with one major exception. Certain defining genetic abnormalities (like t(8;21), inv(16), t(15;17), or PML-RARA) qualify as AML regardless of blast percentage, even at counts as low as 10%.
Major WHO 2022 AML Categories
- AML with recurrent genetic abnormalities — includes t(8;21)/RUNX1-RUNX1T1, inv(16)/CBFB-MYH11, t(15;17)/PML-RARA, KMT2A rearrangements, and newly added entities like AML with NPM1 mutation and AML with CEBPA mutation
- AML with myelodysplasia-related changes — now redefined based on specific mutations (ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, ZRSR2) or cytogenetics rather than morphology alone
- Therapy-related myeloid neoplasms — arising after prior chemotherapy or radiation exposure
- AML, not otherwise specified (NOS) — reserved for cases that don’t fit the above categories, still loosely aligned with FAB subtypes M0–M7
Key Genetic Mutations and Why They Matter
Roughly 97% of AML patients harbor at least one somatic mutation detectable by next-generation sequencing (NGS). These mutations don’t just classify the disease — they dictate prognosis and increasingly guide targeted therapy.
Prognostic Risk Stratification (ELN 2022)
| Risk Category | Genetic Features | Approximate 5-Year OS |
|---|---|---|
| Favorable | t(8;21), inv(16), NPM1 mutated without FLT3-ITD, biallelic CEBPA | 60–70% |
| Intermediate | NPM1 mutated with FLT3-ITD, wild-type NPM1 without FLT3-ITD, t(9;11) | 30–45% |
| Adverse | Complex karyotype (≥3 abnormalities), monosomal karyotype, TP53 mutation, ASXL1, RUNX1, FLT3-ITD with high allelic ratio | 10–20% |
The FLT3-ITD mutation is found in about 25–30% of AML patients and historically carried a poor prognosis. The introduction of FLT3 inhibitors like midostaurin and gilteritinib has changed outcomes for this group — a direct example of how genetic classification translates into survival benefit.
IDH1 and IDH2 mutations (present in ~20% of cases) are now targetable with ivosidenib and enasidenib, respectively. These drugs weren’t possible without the molecular-first approach that goes “beyond” ICD-10 coding.
Diagnosis: What Gets Tested and When
A diagnosis of AML typically starts with a complete blood count (CBC) showing some combination of anemia (hemoglobin often <10 g/dL), thrombocytopenia (platelets <100,000/µL), and a white blood cell count that can range from profoundly low to >100,000/µL.
The definitive diagnosis requires bone marrow aspiration and biopsy with the following workup:
- Morphology — blast count assessment, Auer rod identification
- Flow cytometry — immunophenotyping to confirm myeloid lineage (CD13, CD33, CD34, CD117, MPO)
- Cytogenetics — conventional karyotyping plus FISH for recurrent translocations
- Molecular testing (NGS panel) — at minimum: FLT3, NPM1, CEBPA, IDH1/2, TP53, RUNX1, ASXL1
Turnaround time matters. FLT3 and PML-RARA results are often needed within 48–72 hours because they change initial treatment — APL with PML-RARA is a medical emergency requiring immediate all-trans retinoic acid (ATRA), and FLT3-positive disease gets midostaurin added to induction chemotherapy.
Signs and Symptoms That Trigger Evaluation
AML often presents abruptly. Patients typically describe days to weeks of worsening fatigue, fevers, easy bruising, or bleeding gums. Some develop leukostasis — a medical emergency occurring when WBC exceeds ~100,000/µL, causing respiratory distress, confusion, or stroke-like symptoms.
Other presentations include bone pain, recurrent infections unresponsive to antibiotics, petechiae, and gingival hyperplasia (particularly in monocytic subtypes M4/M5). Median age at diagnosis is 68 years, though AML can strike at any age.
When to See a Doctor
Seek urgent medical attention if you experience unexplained persistent fatigue combined with any of the following: easy bruising or bleeding that won’t stop, recurrent fevers without a clear infection source, bone pain, or a CBC showing abnormal blast cells. AML progresses fast — delays of even days can matter.
If you’re a clinician: any peripheral smear with circulating blasts warrants same-day hematology consultation. Don’t wait for the bone marrow results to start the referral.
Frequently Asked Questions
What is the exact ICD-10 code for AML?
The primary code is C92.0 for acute myeloblastic leukemia not in remission. C92.01 is used for AML in remission, and C92.02 for relapsed disease. Specific subtypes like APL use C92.4.
Why does AML have multiple ICD-10 codes?
Because AML isn’t one disease — it’s a family of related cancers with different biology, treatment approaches, and outcomes. Separating codes for APL (C92.4) from standard AML (C92.0) reflects genuine clinical differences. APL has a cure rate exceeding 90% with ATRA-based therapy, while other AML subtypes carry much worse prognoses.
Is the WHO classification replacing ICD-10 for AML?
No — they serve different purposes. ICD-10 is an administrative and billing system. The WHO classification is a clinical and pathological system that guides treatment decisions. Both are used simultaneously. A patient might be coded as C92.0 (ICD-10) but classified as “AML with mutated NPM1” (WHO), and stratified as favorable risk (ELN).
How does AML genetic testing affect my treatment?
Profoundly. Patients with FLT3 mutations receive targeted FLT3 inhibitors. Those with IDH1/2 mutations may receive ivosidenib or enasidenib. Favorable-risk patients may avoid stem cell transplant in first remission, while adverse-risk patients are typically referred for transplant as soon as possible. Genetic results directly change the treatment plan in over half of all AML cases.
What’s the survival rate for AML?
It varies enormously by age and genetics. Overall 5-year survival is approximately 30% across all age groups. For adults under 60 with favorable-risk genetics, it can exceed 65%. For patients over 75 or those with adverse-risk features like TP53 mutations, median survival may be measured in months. Age, fitness, and molecular profile are the three biggest determinants.
